Susan L. Kelley, M.D.
Chief Medical Officer, Multiple Myeloma Research Foundation

Susan L. Kelley, MD, is Chief Medical Officer of the MMRC, where she provides strategic medical leadership for the myeloma research and development activities supported by the MMRC.

Dr. Kelley has more than 20 years of experience in oncology clinical research and drug development within the pharmaceutical industry. Prior to joining the MMRC, Dr. Kelley served as Vice President and head of Global Oncology Clinical Development at Bayer Healthcare Pharmaceuticals, where she was responsible for the worldwide management of the oncology drug development portfolio and for management of Bayer's oncology drug development and franchise strategies. While at Bayer, she oversaw the successful advance of Nexavar® (sorafenib) through the FDA approval process. Prior to her position at Bayer, Dr. Kelley held several leadership positions in Bristol-Myers Squibb (BMS) Clinical Development.

Dr. Kelley received her medical degree from Duke University School of Medicine. She completed certification in internal medicine at the University of Colorado followed by medical oncology training at the Dana-Farber Cancer Institute in Boston. Prior to joining the pharmaceutical industry, Dr. Kelley was also involved in oncology clinical and laboratory research at Yale University School of Medicine.